Quotient Wealth Partners
VRTX icon

Quotient Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Quotient Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$518K Buy
990
+34
+4% +$17.4K 0.01% 220
2026
Q2 		$475K Sell
956
-39
-4% -$17.3K 0.01% 220
2026
Q1 		$444K Buy
995
+81
+9% +$37.8K 0.01% 215
2025
Q4 		$414K Sell
914
-12
-1% -$5.17K 0.01% 228
2025
Q3 		$363K Sell
926
-145
-14% -$60.6K 0.01% 246
2025
Q2 		$477K Sell
1,071
-59
-5% -$27.2K 0.01% 196
2025
Q1 		$548K Buy
1,130
+149
+15% +$69.4K 0.02% 164
2024
Q4 		$395K Sell
981
-6
-0.6% -$2.78K 0.01% 203
2024
Q3 		$459K Sell
987
-12
-1% -$5.76K 0.02% 181
2024
Q2 		$468K Buy
999
+153
+18% +$66.4K 0.02% 180
2024
Q1 		$354K Sell
846
-93
-10% -$39.3K 0.01% 209
2023
Q4 		$382K Buy
+939
New +$347K 0.01% 203

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Quotient Wealth Partners's VRTX Position: Q3 2026 in Review

Quotient Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 3.6% in Q3 2026, buying an estimated $17.4K and bringing the position to 990 shares worth $518K. The position accounts for 0.01% of the portfolio, ranked #220.

Quotient Wealth Partners first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $548K in Q1 2025. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Quotient Wealth Partners held 990 shares of Vertex Pharmaceuticals worth $518K as of Q3 2026.
  • Quotient Wealth Partners bought 34 Vertex Pharmaceuticals shares in Q3 2026, an estimated $17.4K.
  • Vertex Pharmaceuticals made up 0.01% of Quotient Wealth Partners's portfolio in Q3 2026, its #220 holding.
  • Quotient Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Quotient Wealth Partners's Vertex Pharmaceuticals position peaked at $548K in Q1 2025.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Quotient Wealth Partners's 13F filing for Q3 2026, filed 13 Nov 2026.